By Anna Irrera and Koh Gui Qing NEW YORK (Reuters) - As U.S. authorities scrambled to ramp up the nation's capacity to test for coronavirus last week, at least 100 executives and...
Enzo Biochem (NYSE:ENZ): Q2 EPS of -$0.04 misses by $0.03.Revenue of $27M (+2.8% Y/Y) misses by $0.35M.Shares -2.9%.Press ReleaseNow read: Ironwood Pharmaceuticals (IRWD) Presents...
We issued an updated research report on Menlo Park, CA-based Geron Corporation (NASDAQ:GERN) on Aug 11.Geron is developing anti-cancer therapies based on telomerase inhibitors....
We issued an updated report on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Aug 11.In fact, shares of the company have rallied 12.7% against the Zacks classified...
Nektar Therapeutics’ (NASDAQ:NKTR) shares have declined almost 9% since Aug 8 after the company reported second-quarter results. The biotech reported a wider-than-expected...
Enzo Biochem, Inc. (Enzo) is an integrated diagnostics, clinical lab, and life sciences company that is focused on delivering and applying advanced technology to produce reliable products and services for clinical needs. The Company develops, manufactures and sells technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo's segments include Enzo Clinical Lab, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Lab is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Therapeutics is a biopharmaceutical venture that developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.